A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis

A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Diclofenac Sodium Gel 3% (Actavis) to Solaraze ® (Diclofenac Sodium) Gel 3% (Fougera Pharms) in the Treatment of Actinic Keratosis

To compare the relative efficacy and safety of the test formulation diclofenac sodium gel 3% (Actavis) to the marketed formulation Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms) in the treatment of the actinic keratosis

Study Overview

• Status: Completed
• Conditions: Actinic Keratosis
• Intervention / Treatment: Drug: Diclofenac sodium; Other: Placebo

• Study Type: Interventional
• Enrollment (Actual): 476
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • California
    • Fremont, California, United States
      • Investigator Site 23
    • Long Beach, California, United States
      • Investigator Site 9
    • Newport Beach, California, United States
      • Investigator Site 12
    • San Diego, California, United States
      • Investigator Site 2
    • San Ramon, California, United States
      • Investigator Site 24
  • Colorado
    • Denver, Colorado, United States
      • Investigator Site 14
    • Denver, Colorado, United States
      • Investigator Site 17
  • Florida
    • Brandon, Florida, United States
      • Investigator Site 21
    • Dunedin, Florida, United States
      • Investigator Site 25
    • Fort Myers, Florida, United States
      • Investigator Site 20
    • Jacksonville, Florida, United States
      • Investigator Site 15
    • Miami, Florida, United States
      • Investigator Site 16
    • Ormond Beach, Florida, United States
      • Investigator Site 6
    • Winter Park, Florida, United States
      • Investigator Site 19
  • Georgia
    • Atlanta, Georgia, United States
      • Investigator Site 22
  • Idaho
    • Boise, Idaho, United States
      • Investigator Site 11
  • Illinois
    • Arlington Heights, Illinois, United States
      • Investigator Site 8
  • Indiana
    • Plainfield, Indiana, United States
      • Investigator Site 28
  • Kentucky
    • Louisville, Kentucky, United States
      • Investigator Site 31
  • Minnesota
    • Fridley, Minnesota, United States
      • Investigator Site 27
  • Montana
    • Bozeman, Montana, United States
      • Investigator Site 13
  • North Carolina
    • New Bern, North Carolina, United States
      • Investigator Site 26
    • Raleigh, North Carolina, United States
      • Investigator Site 3
    • Wilmington, North Carolina, United States
      • Investigator Site 18
  • Ohio
    • Cincinnati, Ohio, United States
      • Investigator Site 30
  • Pennsylvania
    • Hazleton, Pennsylvania, United States
      • Investigator Site 1
  • South Carolina
    • Clinton, South Carolina, United States
      • Investigator Site 5
  • Tennessee
    • Johnson City, Tennessee, United States
      • Investigator Site 4
    • Nashville, Tennessee, United States
      • Investigator Site 10
  • Utah
    • West Jordan, Utah, United States
      • Investigator Site 7
  • Virginia
    • Midlothian, Virginia, United States
      • Investigator Site 29

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Signed informed consent form, which meets all criteria of current FDA and HIPAA regulations.
2. Immunocompetent male or non-pregnant, non-lactating female at least 18 years of age.
3. Diagnosis of AK with ≥ 5 and < 10 clinically typical, visible, discrete, nonhyperkeratotic, nonhypertrophic AK lesions each at least 4 mm in diameter on the face and/or bald scalp contained within a 25cm2 treatment area.

4. Women either must be 1 year post-menopausal (no menstrual periods for at least 12 months), surgically sterile, or if they are of child-bearing potential, they must:

   1. Have been using systemic birth control, IUD, or Norplant for at least 28 days prior to the start of treatment period of the study, or used barrier methods such as diaphragm plus spermicide or condom plus spermicide consistently, at least 14 days before study gel administration.
   2. Had a normal menstrual cycle for the month prior to the start of treatment.
   3. Have a negative urine pregnancy test result upon entry into the study.
   4. Agree to use a medically accepted form of birth control (oral, implant, injectable or transdermal contraceptives, intrauterine device, condom plus spermicide, diaphragm plus spermicide) or practice abstinence throughout the study period.
5. Free from any systemic or dermatologic disorder that, in the opinion of the Investigator, will interfere with the study results or increase the risk of AEs.
6. Any skin type or race, providing the skin pigmentation will allow discernment of erythema.
7. Willingness and capability to cooperate to the extent and degree required by the protocol.

Exclusion Criteria:

1. Active gastrointestinal ulceration or bleeding.
2. Current or history of severe renal or hepatic impairment.
3. Presence of atopic dermatitis, basal cell carcinoma, squamous cell carcinoma, eczema, psoriasis, rosacea, sunburn or other possible skin conditions on the face or bald scalp that in the investigator's opinion would interfere with the study assessments.
4. Use within six months prior to randomization of oral isotretinoin.
5. Use within six months prior to randomization on the face or bald scalp of 1) chemical peel, 2) dermabrasion, 3) laser abrasion, 4) PUVA (psoralen plus ultraviolet A) therapy, or 5) UVB therapy
6. Use within one month prior to randomization on the face or bald scalp of 1) cryodestruction or chemodestruction, 2)curettage, 3) photodynamic therapy, 4) surgical excision, 5)topical 5-fluorouracil, 6) topical corticosteroids, 7) topical diclofenac, 8) topical Imiquimod, 9) topical retinoids, or 10) other treatments for actinic keratosis including glycolic acids or over-the-counter products containing retinol, alpha or beta hydroxy acids.
7. Use within one month prior to randomization of 1)immunomodulators or immunosuppressive therapies, 2)interferon, 3) systemic corticosteroids or 4) cytotoxic drugs. (The occasional use of ophthalmic, nasal or inhaled steroids is acceptable and not reason for exclusion)
8. Known allergies to diclofenac sodium, benzyl alcohol, polyethylene glycol monomethyl ether 359, hyaluronate sodium or any excipients in the test or reference gels.
9. Receiving 5-Fluorouracil or other systemic cancer chemotherapy within 6 months prior to randomization.
10. Any condition, medical, psychological, or social, that, in the Investigator's opinion, would interfere with participation in the study.
11. Women who are pregnant, planning pregnancy or lactating.
12. Participation in any investigational drug study within 30 days of randomization or previous participation in this study.
13. Employees of the research center or Investigator.
14. Family members of employees of the research center or Investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Diclofenac Sodium 3% gel - Test; The diclofenac sodium 3% test gel is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough Test Gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.	Drug: Diclofenac sodium; Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.; Other Names: Solaraze
Active Comparator: Diclofenac Sodium 3% gel - Reference; The Reference diclofenac sodium 3% gel (Solaraze®) is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough Reference (Solaraze®) Gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.	Drug: Diclofenac sodium; Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.; Other Names: Solaraze
Placebo Comparator: Placebo gel; The placebo gel (contains no active ingredient) is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough placebo gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.	Other: Placebo; Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.; Other Names: Vehicle base

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Patients With 100% Clearance of All AK Lesions Within the Treatment Area Assessed at Day 90	The primary measure of bioequivalence will be evaluated using those patients who complete the study according to the (PP) population.	90 days

Collaborators and Investigators

• Sponsor: Actavis Inc.
• Investigators: Study Director: Henry lau, PhD, Actavis Inc.

Study record dates

Study Major Dates

• Study Start: March 1, 2013
• Primary Completion (Actual): September 1, 2013
• Study Completion (Actual): September 1, 2013

Study Registration Dates

• First Submitted: October 10, 2013
• First Submitted That Met QC Criteria: October 11, 2013
• First Posted (Estimate): October 16, 2013

Study Record Updates

• Last Update Posted (Actual): July 20, 2020
• Last Update Submitted That Met QC Criteria: July 7, 2020
• Last Verified: July 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Precancerous Conditions; Keratosis, Actinic; Keratosis; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Cyclooxygenase Inhibitors; Diclofenac
• Other Study ID Numbers: 71204901